News

Important valve replacement data expected at ACC.13


 

FROM A PREVIEW OF ACC.13

A list of these and other late-breaking presentations can be found on the ACC.13 website.

Dr. Quinones and Dr. Davies reported having no financial disclosures. Dr. Ballantyne reported receiving speaker and consulting fees and research funds from many pharmaceutical companies. Dr. Mintz has received fees for consulting or speaking from Boston Scientific, Volcano, Medtronic, LightLab, and Pfizer. Dr. O’Gara has been on the Data and Safety Monitoring Board of Lantheus Medical Imaging.

s.boschert@elsevier.com

On Twitter @sherryboschert

Pages

Recommended Reading

Kawasaki disease: long-term cardiovascular risk quantified
MDedge Cardiology
Further STEMI progress requires new focus
MDedge Cardiology
Anticoagulant dabigatran ups the required dose of heparin
MDedge Cardiology
Further STEMI progress requires new focus
MDedge Cardiology
Calcium supplements raise CVD mortality only in men
MDedge Cardiology
Post-stent regimen leaves out aspirin in AF
MDedge Cardiology
Comparing imaging technologies for chest pain in ED
MDedge Cardiology
Heart teams inch into routine cardiac practice
MDedge Cardiology
Poor outcomes seen after carotid intervention non-ST-elevation MI
MDedge Cardiology
Atrial fibrillation device among top trials at ACC 13
MDedge Cardiology